Dopaminergic involvement in adenosine A1 receptor-mediated
antinociception in the tail flick latency model in mice

Malhotra, J; Chaudhary, Geeta; Yk, Gupta

doi:10.1358/mf.2000.22.1.795826

Cited by 10 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been suggested that the antinociceptive effect of OCBZ is mediated, in part, by adenosine A 1 receptor stimulation because it has been reported that OCBZ, as well as CBZ, interacts with brain adenosine A 1 receptors 34 . Stimulation of adenosine A 1 receptors reduced the release of excitatory amino acids and inhibited excitatory post‐synaptic potentials 35,36 and administration of adenosine A 1 receptor agonists produced antinociception in thermal threshold tests 37,38 . In fact, in our preliminary experiment using STZ‐induced diabetic mice, the antinociceptive effect of OCBZ was antagonized by pretreatment with an adenosine antagonist 39 .…”

Section: Discussionmentioning

confidence: 62%

“…34 Stimulation of adenosine A1 receptors reduced the release of excitatory amino acids and inhibited excitatory post-synaptic potentials 35,36 and administration of adenosine A1 receptor agonists produced antinociception in thermal threshold tests. 37,38 In fact, in our preliminary experiment using STZ-induced diabetic mice, the antinociceptive effect of OCBZ was antagonized by pretreatment with an adenosine antagonist. 39 However, such a possibility is non-existent for mexiletine, because the antinociceptive effect of mexiletine was not antagonized by the adenosine antagonist.…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy

Kiguchi

Imamura

Ichikawa

et al. 2004

Clin Exp Pharmacol Physiol

View full text Add to dashboard Cite

1. Diabetic neuropathy is one of the most frequent complications of diabetes mellitus. However, the mechanisms underlying these disorders are not yet well defined and it has been reported that currently available analgesics have hardly any ameliorating effect on painful diabetic neuropathy. 2. The purpose of the present study was to evaluate the antinociceptive effect of oxcarbazepine (OCBZ), a keto derivative of carbamazepine (CBZ), in animal models generally used in pain research and in rats and mice with streptozotocin (STZ)-induced diabetes. In addition, we compared the effect of OCBZ with those of CBZ, mexiletine and morphine. 3. Diabetes was induced by injection of STZ at a dose of 300 mg/kg (i.p.) in mice and 50 mg/kg (i.v.) in rats. Experiments were conducted 2 weeks after STZ injection and those animals with a serum glucose level above 400 mg/dL were used for data analysis. Antinociceptive effects of the drugs were evaluated by the paw withdrawal test (normal, STZ-induced diabetic and carrageenin-injected rats), tail-flick test (normal and STZ-induced diabetic mice) and nociceptive behaviour (formalin-injected mice). 4. In the present study, diabetic mice showed thermal hyperalgesia and diabetic rats exhibited mechanical hyperalgesia. From these results, the STZ-induced diabetic animals used in the present study were found to be suitable for research on painful diabetic neuropathy. In STZ-induced diabetic animals, the antinociceptive effects of OCBZ, CBZ and mexiletine were facilitated, whereas the effect of morphine was attenuated, compared with effects in normal animals. 5. Oxcarbazepine inhibited the formalin-induced biphasic pain responses and increased the nociceptive threshold in the case of carrageenin-induced hyperalgesia. In view of these results, inhibition of substance P-mediated pain transmission may be involved in the antinociceptive action of OCBZ. 6. These results indicate that OCBZ has an analgesic action and is a possible therapeutic agent for the treatment of neuropathic pain, such as occurs in painful diabetic neuropathy.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 89%

Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy

Kiguchi

Imamura

Ichikawa

et al. 2004

Clin Exp Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…1 The chemical structures of l-THP and l-SPD. l-THP and l-SPD belong to tetrahydroprotoberberines (THPBs), sharing the common structure of isoquinoline ring (Malhotra et al 2000;Michael et al 1998). Distinct DA receptors appear to differentially modulate nociception (Frussa-Filho et al 1996;Magnusson and Fisher 2000;Roane et al 1998;Taylor et al 2003).…”

Section: Dopaminergic Systems In Regulating Nociceptionmentioning

confidence: 99%

Recent Development in Studies of Tetrahydroprotoberberines: Mechanism in Antinociception and Drug Addiction

et al. 2007

View full text Add to dashboard Cite

The tetrahydroprotoberberines (THPBs) are compounds isolated from Chinese herbs that possess a unique pharmacological profile as D2 dopamine receptor antagonists and D1 receptor agonists. l-Tetrahydropalmatine (l-THP) and l-stepholidine (SPD), members of the THPB family, were shown to have potential clinical use in the treatment of pain. However, their mechanism of action is not clear. In the past decades, Chinese scientists have made a great deal of effort to explore the mechanisms by which the THPBs and its analogues elicit antinociception and their potential utility in treating drug abuse. It is now clear that the antinociception produced by l-THP is related to inhibition of D(2) dopamine receptors. The present review focuses on the recent progress made in understanding the mechanisms of l-THP- and l-SPD-mediated antinociception and the sequel of drug addiction.

show abstract

“…Previous studies have demonstrated that systemic administration of adenosine and adenosine agonists produce an analgesic action in patients with neuropathic pain (Guieu et al, ; Sharma et al, ; Gilron and Coderre, ). In line with human studies, adenosine and adenosine receptor agonists also have an antinociceptive effect in animal models of acute (Sawynok, ; Malhotra et al, ; Bastia et al, ; Curros‐Criado and Herrero, ), inflammatory (Poon and Sawynok, ; Borghi et al, ; Jarvis et al, ), and nerve injury‐induced (Sjolund et al, ; Lavand'homme and Eisenach, ) neuropathic pain. More recently, studies have demonstrated that stimulation of A1 and A2A adenosine receptors can alleviate diabetic neuropathy (Kumar et al, ; Balasubramanyan and Sharma, ; Katz et al, ).…”

mentioning

confidence: 70%

Role of A3 adenosine receptor in diabetic neuropathy

Yan

Zhang

Feng

et al. 2016

J of Neuroscience Research

View full text Add to dashboard Cite

Neuropathy is the most common diabetic complication. Although the A1 and A2A adenosine receptors are important pharmacological targets in alleviating diabetic neuropathy, the role of the A3 adenosine receptor remains unknown. Because the A3 adenosine receptor regulates pain induced by chronic constriction injury or chemotherapy, its stimulation might also attenuate diabetic neuropathy. This study examines the effects of systemic treatment with the A3 adenosine receptor agonist 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-d-ribofuranuronamide (IB-MECA) on diabetic neuropathy and explores the putative mechanisms underlying its pharmacological effects. We show that IB-MECA alleviated mechanical hyperalgesia and thermal hypoalgesia in mice 2 weeks but not 4 weeks after streptozocin (STZ) treatment. Furthermore, IB-MECA prevented the reduction in sciatic motor nerve conduction velocity and sensory nerve conduction velocity in diabetic mice 2 weeks but not 4 weeks after STZ treatment. Similarly, IB-MECA inhibited the activation of nuclear factor-κB and decreased the generation of tumor necrosis factor-α in the spinal cord of mice 2 weeks but not 4 weeks after STZ treatment. These phenomena were associated with reduction of A3 adenosine receptor expression in the spinal cord after long-term diabetes. Our results suggest that the A3 adenosine receptor plays a critical role in regulating diabetic neuropathy and that reduction in A3 adenosine receptor expression/function might contribute to the progression of diabetic neuropathy. © 2016 Wiley Periodicals, Inc.

show abstract

Dopaminergic involvement in adenosine A1 receptor-mediated antinociception in the tail flick latency model in mice

Cited by 10 publications

References 0 publications

Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy

Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy

Recent Development in Studies of Tetrahydroprotoberberines: Mechanism in Antinociception and Drug Addiction

Role of A3 adenosine receptor in diabetic neuropathy

Contact Info

Product

Resources

About